AU2008324793B2 - Substituted cyclopentanes having prostaglandin activity - Google Patents

Substituted cyclopentanes having prostaglandin activity Download PDF

Info

Publication number
AU2008324793B2
AU2008324793B2 AU2008324793A AU2008324793A AU2008324793B2 AU 2008324793 B2 AU2008324793 B2 AU 2008324793B2 AU 2008324793 A AU2008324793 A AU 2008324793A AU 2008324793 A AU2008324793 A AU 2008324793A AU 2008324793 B2 AU2008324793 B2 AU 2008324793B2
Authority
AU
Australia
Prior art keywords
hydroxy
cyclopentyl
chloro
thiophene
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008324793A
Other languages
English (en)
Other versions
AU2008324793A1 (en
Inventor
Robert M. Burk
Yariv Donde
Jeremiah H. Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40524829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008324793(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2008324793A1 publication Critical patent/AU2008324793A1/en
Application granted granted Critical
Publication of AU2008324793B2 publication Critical patent/AU2008324793B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AU2008324793A 2007-11-09 2008-11-05 Substituted cyclopentanes having prostaglandin activity Ceased AU2008324793B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98684907P 2007-11-09 2007-11-09
US60/986,849 2007-11-09
US12/265,062 US9006464B2 (en) 2007-11-09 2008-11-05 Substituted cyclopentanes having prostaglandin activity
PCT/US2008/082469 WO2009061811A1 (en) 2007-11-09 2008-11-05 Substituted cyclopentanes having prostaglanding activity
US12/265,062 2008-11-05

Publications (2)

Publication Number Publication Date
AU2008324793A1 AU2008324793A1 (en) 2009-05-14
AU2008324793B2 true AU2008324793B2 (en) 2013-12-05

Family

ID=40524829

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008324793A Ceased AU2008324793B2 (en) 2007-11-09 2008-11-05 Substituted cyclopentanes having prostaglandin activity

Country Status (21)

Country Link
US (1) US9006464B2 (enExample)
EP (1) EP2217581B1 (enExample)
JP (1) JP2011503089A (enExample)
KR (1) KR20100101097A (enExample)
CN (2) CN101952261B (enExample)
AR (1) AR069228A1 (enExample)
AU (1) AU2008324793B2 (enExample)
BR (1) BRPI0818902A2 (enExample)
CA (1) CA2705150C (enExample)
CL (1) CL2008003332A1 (enExample)
CO (1) CO6280480A2 (enExample)
DK (1) DK2217581T3 (enExample)
ES (1) ES2432058T3 (enExample)
IL (1) IL205604A (enExample)
MX (1) MX2010005105A (enExample)
NZ (1) NZ585517A (enExample)
RU (1) RU2481339C2 (enExample)
TW (1) TWI411438B (enExample)
UA (1) UA99840C2 (enExample)
WO (1) WO2009061811A1 (enExample)
ZA (1) ZA201003304B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP3991734B1 (en) 2019-06-28 2024-11-27 Gurus BioPharm Inc. Agent for the treatment of alopecia and promoting hair growth

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129552A1 (en) * 2005-12-06 2007-06-07 Allergan, Inc. Therapeutic Substituted Cyclopentanes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7012A (en) * 1850-01-15 Improvement in mowing-machines
IE37602B1 (en) * 1971-05-11 1977-08-31 Ici Ltd Cyclopentane derivatives
JPS5623984B2 (enExample) * 1973-04-19 1981-06-03
US4065472A (en) * 1975-09-29 1977-12-27 Pfizer Inc. 5-(2-Carboxythiophen-5-yl)-16-aryloxy-α-tetranor-ω-tetranorprostaglandins
GB1563201A (en) * 1975-11-05 1980-03-19 Shell Int Research Preparation of herbicidally acitve alanine derivatives
US5698598A (en) * 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
AU2211700A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of glaucoma
US7091231B2 (en) 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7439372B2 (en) * 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
ATE496903T1 (de) * 2007-02-01 2011-02-15 Allergan Inc Thiophenderivate als medikamente zur behandlung von okularer hypertonie

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129552A1 (en) * 2005-12-06 2007-06-07 Allergan, Inc. Therapeutic Substituted Cyclopentanes

Also Published As

Publication number Publication date
US20090124676A1 (en) 2009-05-14
WO2009061811A8 (en) 2009-07-02
EP2217581B1 (en) 2013-07-31
CL2008003332A1 (es) 2011-08-12
RU2010122681A (ru) 2011-12-20
CN102977048A (zh) 2013-03-20
AR069228A1 (es) 2010-01-06
BRPI0818902A2 (pt) 2015-05-12
CO6280480A2 (es) 2011-05-20
CA2705150C (en) 2016-06-14
MX2010005105A (es) 2010-05-27
DK2217581T3 (da) 2013-10-21
UA99840C2 (ru) 2012-10-10
ES2432058T3 (es) 2013-11-29
RU2481339C2 (ru) 2013-05-10
CA2705150A1 (en) 2009-05-14
WO2009061811A1 (en) 2009-05-14
TWI411438B (zh) 2013-10-11
KR20100101097A (ko) 2010-09-16
US9006464B2 (en) 2015-04-14
NZ585517A (en) 2012-08-31
TW200934500A (en) 2009-08-16
EP2217581A1 (en) 2010-08-18
ZA201003304B (en) 2014-03-26
JP2011503089A (ja) 2011-01-27
CN101952261B (zh) 2013-06-12
AU2008324793A1 (en) 2009-05-14
CN101952261A (zh) 2011-01-19
IL205604A (en) 2014-06-30
IL205604A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
US9765065B2 (en) Therapeutic substituted cyclopentanes
CA2705150C (en) Substituted cyclopentanes having prostaglandin activity
KR101561706B1 (ko) 치료제로서의 치환된 감마 락탐
EP2114913B1 (en) Thiophene derivatives useful as ocular hypotensive agents
US8546603B2 (en) Substituted cyclopentanes having prostaglandin activity
WO2006020510A1 (en) Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives and their use as prostaglandin receptor modulators
AU2008208032B2 (en) Substituted arylcylopentenes as therapeutic agents
WO2009097223A1 (en) Substituted gamma lactams as therapeutic agents
HK1181392A (en) Substituted cyclopentanes having prostaglanding activity
WO2006022974A1 (en) 2-heteroarylalkenylcyclopentane heptan - (ene) - oic acid derivatives as therapeutc agents
AU2011209770A1 (en) Therapeutically active cyclopentanes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired